Aside from CAR-T cell therapy and chemotherapy, there is a new method to treat diffuse large B-cell lymphoma: Switzerland's Roche Pharmaceuticals' Gazyva monoclonal antibody. The total cost of this treatment is about half of that of CAR-T cell therapy, roughly between 600,000 to 1,000,000 RMB, and the treatment effect is also very good.
It is evident that currently, the pharmaceutical industry is still dominated by Western countries. The technological barriers established by these pharmaceutical giants over a century are difficult to overcome. In fact, their greatest technological barrier is their research databases which store data from all scientific experiments over the past hundred years. A small portion of this data comes from successful experiments, but the majority comes from failed experiments, and it is the data from these failed experiments that constitute the companies' real trade secrets and hold greater long-term value than successful experiments.
Why?